KR910011798A - 치환된 5-(알킬)카복스아미드 이미다졸 - Google Patents

치환된 5-(알킬)카복스아미드 이미다졸 Download PDF

Info

Publication number
KR910011798A
KR910011798A KR1019900023018A KR900023018A KR910011798A KR 910011798 A KR910011798 A KR 910011798A KR 1019900023018 A KR1019900023018 A KR 1019900023018A KR 900023018 A KR900023018 A KR 900023018A KR 910011798 A KR910011798 A KR 910011798A
Authority
KR
South Korea
Prior art keywords
compound
alkyl
formula
substituted
group
Prior art date
Application number
KR1019900023018A
Other languages
English (en)
Inventor
핀켈스타인 조셉알란
헴펠 주디쓰
맥클로우치 키이난 리챠드
사마넨 제임스
와인스톡 조세프
Original Assignee
스튜아트 알.슈터
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스튜아트 알.슈터, 스미스클라인 비참 코포레이션 filed Critical 스튜아트 알.슈터
Publication of KR910011798A publication Critical patent/KR910011798A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

내용 없음

Description

치환된 5-(알킬)카복스아미드 이미다졸
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (9)

  1. 다음 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염
    상기식에서 R은 아다만틸, 또는 나프틸, 비페닐 또는 펜닐이며, 여기에서 아릴그룹은 각각 비치환되거나 할로, C1-6알킬, C1-6알콕시, OH, CN, CO2R3, 테트라졸 5-일, SO3H, SO2NHR3, NO2, W, SC1-6알킬, SO2C1-6알킬, NHSO2R3, PO(OR3)2, CONR3R3, NR3R3, NR3COH, NR3COC1-6알킬, NR3CON(R3)2, NR3COW, 및 SO2W 중에서 선택된 1 내지 3개의 치환체에 의해 치환되고; R1은 비치환되거나 C1-6알킬, C1-6알콕시, 할로, OH, NO2, NR3R3, W, CO2R3, CN, CONR3R3, NR3COH, 테트라졸-5-일, NR3COC1-6알킬, NR3COW, SC1-6알킬, SO2W 및 SO2C1-6알킬중에서 선택된 1 내지 3개의 치환체에 의해 치환된, C2-10알킬, C3-10알케닐, (CH2)0-8C3-6사이클로알킬 또는 (CH2)0-8페닐이며; X는 단일결합, S, NR3또는 0이고; m은 0내지 4이며; R2는 수소, C1-6알킬, 할로, W, CHO, CH2OH, CO2R3, CONR3R3, NO2, CN, NR3R3또는 페닐이고; R3는 각각 독립적으로 수소 또는 C1-6알킬이며; R4는 수소, C1-8알킬, 티에닐-Y-, 푸릴-Y-, 피라졸릴-Y-, 이미다졸릴-Y-, 티아졸릴-Y-, 피리딜-Y-, 테트라졸릴-Y-. 피로릴-Y-, 트리아졸릴-Y-, 옥사졸릴-Y-, 이속사졸릴-Y-, 또는 페닐-Y-, 이고, 여기에서 아릴 또는 헤테로아릴 그룹은 각각 비치환 되거나, C1-6알킬, C1-6알콕시, 할로, NR3R3, CO2R3, OH, NO2, SO2NHR3, SO2NHR3, SO3H, CONR3R3, W, SO2W, SC1-6알킬, SO2W, C1-6알킬, NR3C(O)Ⅱ, NR3C(O)W 또는 NR3C(O)C1-6알킬에 의해 치환되며; R5는 CO2R3, CONR3R3또는 테트라졸-5-일이고; W는 CqF2q-1(여기에서 q는 1 내지 4이다)이며; Y는 단일결합 또는 직쇄 또는 측쇄의 C1-6알킬이고; n는 0 내지 5이다.
  2. 제1항에 있어서, R이 비치환되거나 클로로, 플루오로, 니트로, 카복시, 트리풀루오로메틸, 메틸, 메톡시, 하이드록시, 설파밀, 시아노, 카보C1-6알콕시, 카바모일 및 테트라졸-5-일 중에서 선택된 1 내지 3개의 치환체에 의해 치환된 페닐이고; R1이 C2-8알킬이며; X가 단일결합 또는 S이고; m이 0.1, 또는 2이며; R2가 수소, 클로로, 플루오로 또는 트리플루오로 메틸이고; R3가 각각 독립적으로 수소 또는 메틸이며; R4가 수소, C1-4알킬, 페닐-(CH2)0-2또는 티에닐-CH2이고, R5가 CO2R3또는 테트라졸-5-일이며, n이 0 내지 3인 화합물 또는 이의 약제학적으로 허용되는 염.
  3. 제1항에 있어서, N-[{2-n-부틸-1(2-클로로페닐)메틸-1H-이미다졸-5-일}메틸카보닐]-L-(2-티에틸)알라닌인 화합물 또는 이의 약제학적으로 허용되는 염.
  4. 제1항에 있어서, N-[{2-n-부틸-1(2-클로로페닐)메틸-1H-이미다졸-5-일}메틸카보닐]-L-페닐알라닌인 화합물 또는 이의 약제학적으로 허용되는 염.
  5. 제1항에 있어서, N-[{1-(2-클로로페닐)메틸-2-프로필티오-1H-이미다졸-5-일}메틸카보닐]-L-페닐알라닌; N-[{2-n-부틸-1(2-클로로페닐)메틸-1H-이미다졸-5-일}메틸카보닐]글리신; N-[{1-(2-클로로페닐)메틸-2-프로필티오-1H-이미다졸-5-일}메틸카보닐]-L-호모페닐알라닌; N-[{2-n-부틸-1(2-클로로페닐)메틸-1H-이미다졸-5-일}메틸카보닐]-L-페닐알라닌; N-[{2-n-부틸-1(2-클로로페닐)메틸-1H-이미다졸-5-일}메틸카보닐]-L-이소루이신; N-[{1-(2-클로로페닐)메틸-2-프로필티오-1H-이미다졸-5-일}카보닐]-D-페닐알라닌; 또는 N-[{1-(2-클로로페닐)메틸-2-프로필티오-1H-이미다졸-5-일}카보닐]글리신인 화합물; 또는 이의 약제학적으로 허용되는 힘.
  6. 제1항 내지 제5항중 어느 한항에 따르는 화합물 및 약제학적으로 허용되는 담체를 함유하는 약제학적 조성물.
  7. 일반식(Ⅱ)의 화합물을 아미드 형성 시약의 존재하에서 일반식(Ⅲ)의 화합물과 반응시킨후, 필요한 경우 (i) R그룹 또는 R1그룹의 페닐잔기가 C1-6알콕시로 치환된 일반식(I)의 화합물을 탈보호시켜, R그룹이 하이드록시로 치환되거나 R1그룹의 페닐잔기가 하이드록시로 치환된 일반식(I)의 화합물로 전환시키거나; (ⅱ) R그룹 또는 R1그룹의 페닐기가 CO2C1-6알킬로 치환된 일반식(I)의 화합물을 가수분해 시켜, R그룹이 카복시로 치환되거나 R1그룹의 페닐잔기가 카복시로 치환된 일반식(I)의 화합물로 전환시키거나; (ⅲ) R그룹 또는 R1그룹의 페닐잔기가 CO2H로 치환된 일반식(I)의 화합물을 할로겐화제로 처리하고, 이어서 적절히 치환된 아민과 반응시켜, R그룹이 CONR2R3로 치환되거나 R1그룹의 페닐잔기가 CONR2R3(여기에서 R3는 수수 또는 C1-6알킬이다)에 의해 치환된 일반식(I)의 화합물로 전환시키거나; (ⅳ) R그룹 또는 R1그룹의 페닐잔기가 시아노로 치환된 일반식(I)의 화합물을 아지드와 반응시켜, R그룹이 테트라졸-5-일로 치환되거나 R1그룹의 페닐잔기가 테트라졸-5-일로 치환된 일반식(I)의 화합물로 전환시키거나; (ⅴ) R5가 CO2C1-6알킬인 일반식(I)의 화합물 가수분해시켜, R5가 카복시인 일반식(I)의 화합물로 전환시키거나; (ⅵ)R5CO2H인 일반식(I)의 화합물을 할로겐화제로 처리하고, 이어서 적절히 치환된 아민과 반응시켜, R5가 CONR3R3(여기에서 R3는 수소 또는 C1-6알킬이다)인 일반식(I)의 화합물로 전환시키거나; (ⅶ) R5가 CONH2인 일반식(I)의 화합물을 옥살릴클로라이드/디메틸포름아미드로 처리하고, 이어서 아지드와 반응시켜, R5가 테트라졸-5-일인 일반식(I)의 화합물로 전환시키고; 그후 임의로 약제학적으로 허용되는 염을 생성시킴을 특징으로 하여, 제1항에서 정의된 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법.
    H2NC(R3)(R4)(R6) (Ⅲ)
    상기식에서 R2, R3, R4, X, m 및 n은 제1항에서 정의한 바와같고; R1및 R1´는 각각 R 및 R1에 대하여 제1항에서 정의한 바와같으며, 단, R´그룹상의 치환체 및 R1´ 그룹의 페닐잔기상의 치환체는 테트라졸-5-일, OH, CO2H 또는 COR3R3를 포함해서는 안되고; R6는 CO2C1-6알킬 또는 1H-테트라졸-5-일이다.
  8. 안지오텐신 Ⅱ수용체 길항질이 인자인 질병을 치료하는 약제를 제조하는데 있어서, 제1항에서 정의한 바와같은 일반식(I)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
  9. 고혈압증 치료용 약제를 제조하는데 있어서 제1항에서 정의한 바와같은 일반식(I)의 화합물 또는 이의 약제학적 으로 허용되는 염의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900023018A 1989-12-29 1990-12-29 치환된 5-(알킬)카복스아미드 이미다졸 KR910011798A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45905189A 1989-12-29 1989-12-29
US07/459,051 1989-12-29

Publications (1)

Publication Number Publication Date
KR910011798A true KR910011798A (ko) 1991-08-07

Family

ID=23823211

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900023018A KR910011798A (ko) 1989-12-29 1990-12-29 치환된 5-(알킬)카복스아미드 이미다졸

Country Status (9)

Country Link
EP (1) EP0437103A3 (ko)
JP (1) JPH07215944A (ko)
KR (1) KR910011798A (ko)
AU (1) AU6847490A (ko)
CA (1) CA2032289A1 (ko)
IE (1) IE904707A1 (ko)
NZ (1) NZ236592A (ko)
PT (1) PT96399A (ko)
ZA (1) ZA9010433B (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210079A (en) * 1988-01-07 1993-05-11 E. I. Du Pont De Nemours And Company Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
ATE146076T1 (de) * 1990-06-22 1996-12-15 Du Pont Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
NZ238688A (en) * 1990-06-28 1992-05-26 Smithkline Beecham Corp Substituted histidines: pharmaceutical compositions, preparation and uses thereof
NZ239161A (en) * 1990-07-31 1994-01-26 Smithkline Beecham Corp Substituted [1h-imidazol-5-yl] alkanoic acid derivatives; medicaments,
US5616599A (en) * 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5179117A (en) * 1991-12-20 1993-01-12 Du Pont Merck Pharmaceutical Company Antihypercholesterolemic 2-substituted imidazoles
US5364869A (en) * 1992-03-09 1994-11-15 Abbott Laboratories Heterocycle-substituted benzyaminopyridine angiotensin II receptor antagonists
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
CZ283315B6 (cs) * 1992-12-17 1998-02-18 Sankyo Company Limited Bifenylové deriváty, způsob výroby a farmaceutické prostředky k léčení hypertense a srdečních onemocnění, které tyto deriváty obsahují
US5972984A (en) * 1995-06-06 1999-10-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5756528A (en) * 1995-06-06 1998-05-26 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AU2005221683A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CA2688161C (en) 2007-06-04 2020-10-20 Kunwar Shailubhai Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
US7834041B2 (en) 2007-09-07 2010-11-16 Theravance, Inc. Dual-acting antihypertensive agents
WO2009076288A1 (en) 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
EP2297113A1 (en) 2008-04-29 2011-03-23 Theravance, Inc. Dual-acting antihypertensive agents
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
WO2010011821A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. Dual-acting antihypertensive agents
JP5833000B2 (ja) 2009-07-07 2015-12-16 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 二重に作用するピラゾール抗高血圧症薬
EP2456762B1 (en) 2009-07-22 2013-10-16 Theravance, Inc. Dual-acting oxazole antihypertensive agents
WO2011090929A1 (en) 2010-01-19 2011-07-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
FR3027900B1 (fr) * 2014-11-05 2018-02-23 Centre National De La Recherche Scientifique Utilisation de derives halogenes de l'histidine a titre de sel d'electrolyte dans une cellule photovoltaique a colorants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5671073A (en) * 1979-11-12 1981-06-13 Takeda Chem Ind Ltd Imidazole derivative
US4532331A (en) * 1983-04-12 1985-07-30 Smithkline Beckman Corporation 1-Benzyl-2-aminomethyl imidazole derivatives
DE3608143A1 (de) * 1986-03-12 1987-09-17 Hoechst Ag 1-phenylimidazolcarbonsaeureamide, ihre herstellung sowie ihre verwendung als wachstumsregulatoren
DE3629064A1 (de) * 1986-08-27 1988-03-03 Hoechst Ag 2,3,6-substituierte phenylimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als wachstumgsregulatoren
US4762850A (en) * 1987-03-24 1988-08-09 Smithkline Beckman Corporation Dopamine-beta-hydroxylase inhibitors
EP0305330A1 (de) * 1987-08-25 1989-03-01 Ciba-Geigy Ag Imidazolderivate

Also Published As

Publication number Publication date
PT96399A (pt) 1991-10-15
CA2032289A1 (en) 1991-06-30
IE904707A1 (en) 1991-07-17
EP0437103A2 (en) 1991-07-17
NZ236592A (en) 1991-11-26
ZA9010433B (en) 1992-01-29
EP0437103A3 (en) 1991-07-24
AU6847490A (en) 1991-07-04
JPH07215944A (ja) 1995-08-15

Similar Documents

Publication Publication Date Title
KR910011798A (ko) 치환된 5-(알킬)카복스아미드 이미다졸
KR910009669A (ko) 치환된 n-(이미다졸릴)알킬 알라닌 유도체
KR910000658A (ko) 이미다졸릴- 알케노산
DE69329727D1 (de) Neue imidazol derivate, ihre herstellung und therapeutische verwendung
KR910007918A (ko) 치환된5-[(테트라졸릴)알케닐]이미다졸
KR910000659A (ko) 이미다졸릴-알케노산
ATE211147T1 (de) Tripeptidisches antithrombotisches mittel
KR840008016A (ko) 융합 이미다졸 화합물의 제조방법
TR199901674T2 (ko)
KR930004276A (ko) 치환된 헤테로사이클류
KR910006236A (ko) 피라졸 유도체,이의 제조방법 및 이를 함유한 약학조성물
KR900009598A (ko) 혈관평활근 이완작용을 가진 화합물과 그의 제조방법
KR840001952A (ko) N-(4-(3-아미노프로필) 아미노부틸)-2-(ω)-과니디노-지방산-아미도)-2-치환된-에탄아미드 이들의 염 및 이들의 제조방법
CA2176935A1 (fr) Arylpiperazines derivees d'indole comme ligands pour les recepteurs 5 ht1-like 5 ht1b et 5 ht1d
NO941857D0 (no) Tetrazolylfenylborsyremellomprodukter for syntese av AII-reseptorantagonister
RU94034117A (ru) Производные азола, способы их получения и антигрибковое средство
DE69329293T2 (de) Molekülmarkierung mit 2-hydrazinopyridinderivate
US4912024A (en) Photographic material having releasable compound
CA2040319A1 (en) Sulfonylamino substituted bicyclyl hydroxamic acid derivatives
NZ334030A (en) Synthesis of bisindolylmalimides
KR840003250A (ko) 3-(1h-테트라졸-5-일)-4-(3h)-퀴나졸리논의 제조방법
FI965289A0 (fi) DP-1:n ja muiden DP-proteiinien estäjien määritys
ATE151749T1 (de) Synthese von indolen durch dehydrierung von indolinen
JPH07505633A (ja) 新規フェンサイクリジン誘導体，タンパクおよびポリペプチドフェンサイクリジン誘導共役体および標識
US3329690A (en) Process for the manufacture of secondary amines which comprises reacting an n-substituted imino ester with a reactively esterified lower alkanol and hydrolyzing the resulting reaction product

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid